Evidence map›Paper›PMID 26787600›Full record

ArticleScientific reports2016

Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.

Jason Roszik, Chang-Jiun Wu, Alan E Siroy, Alexander J Lazar, Michael A Davies, Scott E Woodman, Lawrence N Kwong

Abstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.The Journal of investigative dermatology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.Thyroid : official journal of the American Thyroid Association · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jason RoszikDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.
Chang-Jiun WuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.
Alan E SiroyDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.
Alexander J LazarDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.
Scott E WoodmanDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.
Lawrence N KwongDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.

Funding

UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
Multidisciplinary Subspecialty Pathology Research Fellowship ProgramT32CA163185 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CZERNIAK, BOGDAN A, KEYOMARSI, KHANDAN · 2011 to 2015
$1.7M
The Role of the PI3K-AKT Pathway in Melanoma Brain MetastasisR01CA154710 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2011 to 2015
$1.6M
NCI NIH HHS P50 CA093459NCI NIH HHS R01 CA154710NCI NIH HHS T32 CA163185
6 · The paper itself

Abstract

Somatic copy number alterations (SCNAs) affecting oncogenic drivers have a firmly established role in promoting cancer. However, no agreed-upon standard exists for calling locus-specific amplifications and deletions in each patient sample. Here, we report the correlative analysis of copy number amplitude and length with gene expression across 6,109 samples from The Cancer Genome Atlas (TCGA) dataset across 16 cancer types. Using specificity, sensitivity, and precision-based scores, we assigned optimized amplitude and length cutoffs for nine recurrent SCNAs affecting known oncogenic drivers, using mRNA expression as a functional readout. These cutoffs captured the majority of SCNA-driven, highly-expression-altered samples. The majority of oncogenes required only amplitude cutoffs, as high amplitude samples were almost invariably focal; however, CDKN2A and PTEN uniquely required both amplitude and length cutoffs as primary predictors. For PTEN, these extended to downstream AKT activation. In contrast, SCNA genes located peri-telomerically or in fragile sites showed poor expression-copy number correlations. Overall, our analyses identify optimized amplitude and length cutoffs as efficient predictors of gene expression changes for specific oncogenic SCNAs, yet warn against one-size-fits-all interpretations across all loci. Our results have implications for cancer data analyses and the clinic, where copy number and mutation data are increasingly used to personalize cancer therapy.

Indexed as

DNA Copy Number VariationsGene Expression Regulation, NeoplasticGenetic LociOncogenesCarcinogenesisDatabases, GeneticGene DosageHumansNeoplasmsROC CurveTumor Suppressor ProteinsTumor Suppressor Proteins

Identifiers

PMID26787600
PMCPMC4726397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.